The National AI Application Pilot Base for the Medical Sector unveiled phased achievements, introducing five core medical AI breakthroughs and nine flagship applications aimed at advancing AI-enabled healthcare and expanding intelligent medical services across China.

On launch day, the base signed cooperation agreements with four Shanghai districts, eight research institutes, 28 hospitals, and 20 tech firms to form a government-industry-university-research ecosystem.

Several applications have achieved large-scale deployment, including a hepatobiliary tumor AI agent used in 122 institutions serving over 1 million people, and a chest-imaging multi-diagnosis agent that has processed more than 2.5 million cases across about 20 domestic hospitals, boosting efficiency and precision medicine.

Launched in 2025 under Zhongshan Hospital with national and municipal guidance, the base built an integrated pilot verification platform covering computing power, medical data, large models, and clinical validation to support scalable AI use in medicine.

Looking ahead, the base plans to accelerate achievement transformation, build a global medical AI innovation hub, and contribute to Healthy China by injecting technology-driven momentum into healthcare and public health.

The five breakthroughs target industry challenges: a domestic computing power platform with world-class performance using domestic models on domestic chips; six vertical medical large models for diverse clinical scenarios; a national demonstrative medical AI data infrastructure; the MedBench 4.0 testing platform for Chinese medical large models; and translating lab technologies into clinical applications.

The nine flagship applications span clinical diagnosis, medical device R&D, AI-driven drug discovery, and brain-computer interface technologies, including Zhongshan Hospital's Guanxin cardiovascular AI agent, Renji Hospital's urology AI agent serving over 500,000 patients, and Huashan Hospital's invasive brain-computer interface device—the first in China to receive a Class III medical device certificate.